% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Renovanz:274242,
author = {M. Renovanz and S. C. Kurz and J. Rieger and B. Walter and
H. Becker and H. Hille and P. Bombach and D. Rieger and L.
Grosse and L. Häusser and M. Skardelly and D. J. Merk and
F. Paulsen and E. Hoffmann and C. Gani and M. Neumann and R.
Beschorner$^*$ and O. Rieß$^*$ and C. Roggia and C.
Schroeder and S. Ossowski and S. Armeanu-Ebinger and A.
Gschwind and S. Biskup and M. Schulze and F. Fend$^*$ and S.
Singer$^*$ and L. Zender$^*$ and C. Lengerke$^*$ and S. Y.
Brucker$^*$ and T. Engler$^*$ and A. Forschner$^*$ and A.
Stenzl$^*$ and O. Kohlbacher$^*$ and S. Nahnsen$^*$ and G.
Gabernet and S. Fillinger and B. Bender and U. Ernemann and
Ö. Öner and J. Beha and H. S. Malek and Y. Möller and K.
Ruhm and M. Tatagiba and J. Schittenhelm$^*$ and M.
Bitzer$^*$ and N. Malek$^*$ and D. Zips$^*$ and G.
Tabatabai$^*$},
title = {{C}linical outcome of biomarker-guided therapies in adult
patients with tumors of the nervous system.},
journal = {Neuro-oncology advances},
volume = {5},
number = {1},
issn = {2632-2498},
address = {Oxford},
publisher = {Oxford University Press},
reportid = {DKFZ-2023-00528},
pages = {1-14},
year = {2023},
abstract = {The clinical utility of molecular profiling and targeted
therapies for neuro-oncology patients outside of clinical
trials is not established. We aimed at investigating
feasibility and clinical utility of molecular profiling and
targeted therapy in adult patients with advanced tumors in
the nervous system within a prospective observational
study.molecular tumor board (MTB)@ZPM (NCT03503149) is a
prospective observational precision medicine study for
patients with advanced tumors. After inclusion of patients,
we performed comprehensive molecular profiling, formulated
ranked biomarker-guided therapy recommendations based on
consensus by the MTB, and collected prospective clinical
outcome data.Here, we present initial data of 661 adult
patients with tumors of the nervous system enrolled by
December 31, 2021. Of these, 408 patients were presented at
the MTB. Molecular-instructed therapy recommendations could
be made in 380/408 $(93.1\%)$ cases and were prioritized by
evidence levels. Therapies were initiated in 86/380
$(22.6\%)$ cases until data cutoff. We observed a
progression-free survival ratio >1.3 in $31.3\%$ of
patients.Our study supports the clinical utility of
biomarker-guided therapies for neuro-oncology patients and
indicates clinical benefit in a subset of patients. Our data
might inform future clinical trials, translational studies,
and even clinical care.},
keywords = {MTB@ZPM-001 (NCT03503149) (Other) / Molecular tumor board
(Other) / precision medicine (Other) / real-world data
(Other) / targeted therapy (Other)},
cin = {TU01},
ddc = {610},
cid = {I:(DE-He78)TU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36915613},
pmc = {pmc:PMC10007909},
doi = {10.1093/noajnl/vdad012},
url = {https://inrepo02.dkfz.de/record/274242},
}